| scholarly article | Q13442814 |
| P50 | author | Maria G Tektonidou | Q57034988 |
| P2093 | author name string | Evrydiki Kravvariti | |
| Eleni Palli | |||
| P2860 | cites work | Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. | Q55177568 |
| Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus | Q81517370 | ||
| Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort | Q83954302 | ||
| Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells | Q84513241 | ||
| Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway | Q84626226 | ||
| The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment | Q86328050 | ||
| Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH | Q88037641 | ||
| Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use | Q88458190 | ||
| Type I interferon blockade in systemic lupus erythematosus: where do we stand? | Q26865441 | ||
| Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus | Q28212039 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Interferon and granulopoiesis signatures in systemic lupus erythematosus blood | Q29615064 | ||
| Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study | Q30234540 | ||
| Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients | Q33412915 | ||
| The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features | Q33420116 | ||
| Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis | Q36042432 | ||
| Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression | Q36745815 | ||
| IFNα serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients | Q37500133 | ||
| Activation of the type I interferon pathway in primary Sjogren’s syndrome | Q37776830 | ||
| Anti-interferon alpha treatment in SLE. | Q38097198 | ||
| Emerging Therapies in Antiphospholipid Syndrome | Q38782057 | ||
| NETopathies? Unraveling the Dark Side of Old Diseases through Neutrophils | Q38998709 | ||
| Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome | Q39586997 | ||
| Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome | Q39608521 | ||
| Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools | Q40649226 | ||
| Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome | Q41915133 | ||
| Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target | Q42162703 | ||
| Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients | Q44830352 | ||
| Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. | Q47680027 | ||
| Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. | Q47743642 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| primary antiphospholipid syndrome | Q63878006 | ||
| P304 | page(s) | 487 | |
| P577 | publication date | 2019-03-15 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations | |
| P478 | volume | 10 |
| Q93127155 | An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers | cites work | P2860 |
Search more.